Cargando…

A predictive analysis of the SP120 and 10D7G2 antibodies for human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma treated with adjuvant gemcitabine

Expression of human equilibrative nucleoside transporter 1 (hENT1) in pancreatic ductal adenocarcinoma (PDAC) has been postulated to be a marker of sensitivity to gemcitabine. However, heterogeneity in the studies attempting to quantify hENT1 expression in patients with PDAC treated with gemcitabine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kalloger, Steve E, Riazy, Maziar, Tessier‐Cloutier, Basile, Karasinska, Joanna M, Gao, Dongxia, Peixoto, Renata D, Samimi, Setareh, Chow, Christine, Wong, Hui‐Li, Mackey, John R, Renouf, Daniel J, Schaeffer, David F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5527321/ https://www.ncbi.nlm.nih.gov/pubmed/28770102 http://dx.doi.org/10.1002/cjp2.75

Ejemplares similares

Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions
por: Spratlin, Jennifer L., et al.
Publicado: (2010)

Human equilibrative nucleoside transporter 1 (hENT1) expression as a predictive biomarker for gemcitabine chemotherapy in biliary tract cancer
por: Kim, Jaihwan, et al.
Publicado: (2018)

Prognostic and predictive value of human equilibrative nucleoside transporter 1 (hENT1) in extrahepatic cholangiocarcinoma: a translational study
por: Boyd, Lenka N. C., et al.
Publicado: (2023)

Bidirectional transport of 2-chloroadenosine by equilibrative nucleoside transporter 4 (hENT4): Evidence for allosteric kinetics at acidic pH
por: Tandio, David, et al.
Publicado: (2019)

Gestational Diabetes—Placental Expression of Human Equilibrative Nucleoside Transporter 1 (hENT1): Is Delayed Villous Maturation an Adaptive Pattern?
por: Giacometti, Cinzia, et al.
Publicado: (2023)

Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status
por: Raffenne, Jerome, et al.
Publicado: (2019)

ET-7 Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma
por: Yamamoto, Masahiro, et al.
Publicado: (2021)

Targeting the equilibrative nucleoside transporter ENT1 in Huntington disease
por: Guitart, Xavier, et al.
Publicado: (2017)

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA
por: Aughton, Karen, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
por: Hwang, Dae Wook, et al.
Publicado: (2020)

hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients
por: Meijer, Laura L., et al.
Publicado: (2016)

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression
por: Guo, Zhongyi, et al.
Publicado: (2018)

Decreased erythrocyte nucleoside transport and hENT1 transporter expression in glucose 6-phosphate dehydrogenase deficiency
por: Al-Ansari, Mohammad, et al.
Publicado: (2015)

HIF-1–dependent repression of equilibrative nucleoside transporter (ENT) in hypoxia
por: Eltzschig, Holger K., et al.
Publicado: (2005)

hENT1’s role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients
por: Wang, Wei, et al.
Publicado: (2023)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer
por: Xi, Yue, et al.
Publicado: (2022)

Functional Characterization of the Saccharomyces cerevisiae Equilibrative Nucleoside Transporter 1 (ScENT1)
por: Boswell-Casteel, Rebba C., et al.
Publicado: (2018)

Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer
por: Elander, N. O., et al.
Publicado: (2018)

Equilibrative nucleoside transporter 1 (ENT1) is critical for pollen germination and vegetative growth in Arabidopsis
por: Bernard, Carsten, et al.
Publicado: (2011)

Changes in aortic reactivity associated with the loss of equilibrative nucleoside transporter 1 (ENT1) in mice
por: Best, K. Arielle, et al.
Publicado: (2018)

Differential Inhibition of Equilibrative Nucleoside Transporter 1 (ENT1) Activity by Tyrosine Kinase Inhibitors
por: Jouan, Elodie, et al.
Publicado: (2021)

Targeting the Plasmodium vivax equilibrative nucleoside transporter 1 (PvENT1) for antimalarial drug development
por: Deniskin, Roman, et al.
Publicado: (2015)

N-linked glycosylation of N48 is required for equilibrative nucleoside transporter 1 (ENT1) function
por: Bicket, Alex, et al.
Publicado: (2016)

Targeting myocardial equilibrative nucleoside transporter ENT1 provides cardioprotection by enhancing myeloid Adora2b signaling
por: Ruan, Wei, et al.
Publicado: (2023)

Advancing the Care of Pancreatic Cancer Patients: Moving Beyond Just Tumour Tissue
por: Kalloger, Steve E, et al.
Publicado: (2021)

Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
por: Vincenzi, Bruno, et al.
Publicado: (2017)

Programmed cell death ligand 1 cut-point is associated with reduced disease specific survival in resected pancreatic ductal adenocarcinoma
por: Tessier-Cloutier, Basile, et al.
Publicado: (2017)

Regulation of hepatic glucose production and AMPK by AICAR but not by metformin depends on drug uptake through the equilibrative nucleoside transporter 1 (ENT1)
por: Logie, Lisa, et al.
Publicado: (2018)

Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer
por: Eto, K, et al.
Publicado: (2013)

Human equilibrative nucleoside transporter‐1 and deoxycytidine kinase can predict gemcitabine effectiveness in Egyptian patients with Hepatocellular carcinoma
por: Attia, Fadia, et al.
Publicado: (2020)

Decreased Equilibrative Nucleoside Transporter 1 (ENT1) Activity Contributes to the High Extracellular Adenosine Levels in Mesenchymal Glioblastoma Stem-Like Cells
por: Alarcón, Sebastián, et al.
Publicado: (2020)

Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis.
por: Pressacco, J., et al.
Publicado: (1995)

Functional characterization of human equilibrative nucleoside transporter 1
por: Huang, Weiyun, et al.
Publicado: (2016)

Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles
por: Naes, Safaa M., et al.
Publicado: (2020)

Prognostic Value of Human Equilibrative NucleosideTransporter1 in Pancreatic Cancer Receiving Gemcitabin-Based Chemotherapy: A Meta-Analysis
por: Liu, Zhu-Qing, et al.
Publicado: (2014)

Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer
por: Elebro, Jacob, et al.
Publicado: (2016)

SKM-1细胞地西他滨耐药机制中hENT1功能的研究
Publicado: (2015)

Predictive role of human equilibrative nucleoside transporter 1 in patients with pancreatic cancer treated by curative resection and gemcitabine-only adjuvant chemotherapy
por: Aoyama, Toru, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_013fgk3sm9rc39jb84n05h44nh